ANNOVIS BIO (ANVS) Stock Price, Quote, News and Overview
NYSE:ANVS - New York Stock Exchange, Inc. - US03615A1088 - Common Stock - Currency: USD
ANVS Quote, Performance and Key Statistics
2.08
+0.07 (+3.48%)
The current stock price of ANVS is 2.08 USD. In the past month the price increased by 26.83%. In the past year, price decreased by -71.47%.
ANVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About ANVS
Company Profile
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Company Info
ANNOVIS BIO
101 Lindenwood Drive, Suite 225
Malvern PENNSYLVANIA 19312 US
CEO: Maria Maccecchini
Employees: 12
Phone: 14848753192
ANNOVIS BIO / ANVS FAQ
What is the stock price of ANNOVIS BIO today?
The current stock price of ANVS is 2.08 USD. The price increased by 3.48% in the last trading session.
What is the ticker symbol for ANNOVIS BIO stock?
The exchange symbol of ANNOVIS BIO is ANVS and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is ANVS stock listed?
ANVS stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for ANNOVIS BIO stock?
13 analysts have analysed ANVS and the average price target is 33.15 USD. This implies a price increase of 1493.75% is expected in the next year compared to the current price of 2.08. Check the ANNOVIS BIO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANNOVIS BIO worth?
ANNOVIS BIO (ANVS) has a market capitalization of 40.54M USD. This makes ANVS a Nano Cap stock.
How many employees does ANNOVIS BIO have?
ANNOVIS BIO (ANVS) currently has 12 employees.
What are the support and resistance levels for ANNOVIS BIO (ANVS) stock?
ANNOVIS BIO (ANVS) has a support level at 1.6 and a resistance level at 2.15. Check the full technical report for a detailed analysis of ANVS support and resistance levels.
Should I buy ANNOVIS BIO (ANVS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANVS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANVS, evaluating the profitability, health, valuation and growth aspects
- ANNOVIS BIO (ANVS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANNOVIS BIO (ANVS) Sales and EPS estimates to see what analysts future expectations are.
- ANNOVIS BIO (ANVS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANNOVIS BIO (ANVS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANNOVIS BIO (ANVS) Stock Chart to make your own analysis
- ANNOVIS BIO (ANVS) Latest news and press-releases to stay up to date.
Does ANNOVIS BIO (ANVS) stock pay dividends?
ANVS does not pay a dividend.
When does ANNOVIS BIO (ANVS) report earnings?
ANNOVIS BIO (ANVS) will report earnings on 2025-08-12, before the market open.
What is the Price/Earnings (PE) ratio of ANNOVIS BIO (ANVS)?
ANNOVIS BIO (ANVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.04).
What is the Short Interest ratio of ANNOVIS BIO (ANVS) stock?
The outstanding short interest for ANNOVIS BIO (ANVS) is 11.71% of its float. Check the ownership tab for more information on the ANVS short interest.
ANVS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ANVS. When comparing the yearly performance of all stocks, ANVS is a bad performer in the overall market: 89.65% of all stocks are doing better.
ANVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANVS. The financial health of ANVS is average, but there are quite some concerns on its profitability.
ANVS Financial Highlights
Over the last trailing twelve months ANVS reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 59.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -176.58% | ||
| ROE | -264.2% | ||
| Debt/Equity | 0 |
ANVS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ANVS. The Buy consensus is the average rating of analysts ratings from 13 analysts.